@article{b05eae696e2b45fab9e7f19068e5c230,
title = "Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia",
keywords = "Immunotherapy, Monoclonal antibodies, Multiple myeloma, Plasma cell dyscrasias, Targeted therapy",
author = "Parrondo, {Ricardo D.} and Moustafa, {Muhamad Alhaj} and Craig Reeder and Taimur Sher and Vivek Roy and Eli Muchtar and Rahma Warsame and Victoria Alegria and Wilson Gonsalves and David Dingli and Suzanne Hayman and Prashant Kapoor and Chanan-Khan, {Asher A.} and Sikander Ailawadhi",
note = "Funding Information: M.A.M. performs consultancy for Acrotech. P.K. received honoraria from Celgene and Takeda, preforms consultancy for Cellectar and Sanofi, and receives research funding from Janssen , Sanofi , Amgen , Takeda , and GlaxoSmithKline . D.D. performs consultancy for Apellis, Alexion, Janssen, Sanofi-Genzyme, Millennium, and Rigel and receives research funding rom Bristol Myers Squibb and Karyopharm Therapeutics. S.A. receives honoraria from Celgene and Takeda and research funding from Amgen , Janssen , Pharmacyclics , Cellectar , Bristol-Myers Squibb , Phosphatin , and MedImmune . The other authors have stated that they have no conflict of interest. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
doi = "10.1016/j.clml.2021.01.002",
language = "English (US)",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
}